Search in:

Advanced search

Clinical Ophthalmology Volume 9, 2015 - Issue

Submit an article Journal homepage

Open access

197

Views

CrossRef citations to date

Altmetric

Original Research

Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey

Monica Varano1 Department of Ophthalmology, Fondazione GB Bietti-IRCCs, Rome, ItalyCorrespondence[email protected]

Nicole Eter2 Department of Ophthalmology, University of Münster, Münster, Germany

Steve Winyard3 Department of Policy and Campaigns, Royal National Institute of Blind People, London, UK

Kim U Wittrup-Jensen4 Bayer Pharma AG, Berlin, Germany

Rafael Navarro5 Instituto de Microcirugía Ocular, Barcelona, Spain

Julie Heraghty6 Macular Disease Foundation Australia, Sydney, NSW, Australia

Pages 2243-2250 | Published online: 01 Dec 2015

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

CardarelliWJSmithRAManaged care implications of age-related ocular conditionsAm J Manag Care2013195 supplS85S9123725500
PubMed Web of Science ®Google Scholar
SchmierJKJonesMLHalpernMTThe burden of age-related macular degenerationPharmacoeconomics200624431933416605279
PubMed Web of Science ®Google Scholar
WongWLSuXLiXCheungCMKleinRChengCYWongTYGlobal prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysisLancet Glob Health201422e106e11625104651
PubMed Web of Science ®Google Scholar
Acess EconomicsThe Global Economic Cost of Visual ImpairmentInternational Council of Ophthalmology Web site Available from: http://www.icoph.org/dynamic/attachments/resources/globalcostofvi_finalreport.pdfAccessed October 6, 2014
Google Scholar
HeierJSBrownDMChongVVIEW 1 and VIEW 2 Study GroupsIntravitreal aflibercept (VEGF trap-eye) in wet age-related macular degenerationOphthalmology2012119122537254823084240
PubMed Web of Science ®Google Scholar
Schmidt-ErfurthUKaiserPKKorobelnikJFIntravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studiesOphthalmology2014121119320124084500
PubMed Web of Science ®Google Scholar
BrownDMKaiserPKMichelsMANCHOR Study GroupRanibizumab versus verteporfin for neovascular age-related macular degenerationN Engl J Med2006355141432144417021319
PubMed Web of Science ®Google Scholar
RosenfeldPJBrownDMHeierJSMARINA Study GroupRanibizumab for neovascular age-related macular degenerationN Engl J Med2006355141419143117021318
PubMed Web of Science ®Google Scholar
HolekampNMLiuYYehWSClinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degenerationAm J Ophthalmol2014157482583324388973
PubMed Web of Science ®Google Scholar
GohilRCrosby-NwaobiRForbesABurtonBHykinPSivaprasadSCaregiver burden in patients receiving ranibizumab therapy for neovascular age related macular degenerationPLoS One2015106e012936126056840
PubMed Web of Science ®Google Scholar
RealJPLunaJDUrrets-ZavaliaJADe SantisMOPalmaSDGraneroGEAccessibility as a conditioning factor in treatment for exudative age-related macular degenerationEur J Ophthalmol201323685786423661541
PubMed Web of Science ®Google Scholar
MattheESandnerDFrühzeitige behandlung mit ranibizumab (Lucentis®) bei exsudativer AMDOphthalmologe2011108323724321170652
PubMed Web of Science ®Google Scholar
JavittJCZlatevaGPEarnshawSRCost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuityValue Health200811456357418179676
PubMed Web of Science ®Google Scholar
SchmierJKHalpernMTCovertDDelgadoJSharmaSImpact of visual impairment on use of care giving by individuals with age-related macular degenerationRetina20062691056106217151494
PubMed Web of Science ®Google Scholar
GopinathBKifleyACumminsRHeraghtyJMitchellPPredictors of psychological distress in caregivers of older persons with wet age-related macular degenerationAging Ment Health201519323924624943714
PubMed Web of Science ®Google Scholar
LadEMHammillBGQuallsLGWangFCousinsSWCurtisLHAnti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare benefciariesAm J Ophthalmol2014158353754324857687
PubMed Web of Science ®Google Scholar
HolzFGTadayoniRBeattySMulti-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degenerationBr J Ophthalmol201499222022625193672
PubMed Web of Science ®Google Scholar
RegilloCDBrownDMAbrahamPRandomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1Am J Ophthalmol2008145223924818222192
PubMed Web of Science ®Google Scholar
Schmidt-ErfurthUEldemBGuymerREXCITE Study GroupEfficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE studyOphthalmology2011118583183921146229
PubMed Web of Science ®Google Scholar
AzzoliniCTorreggianiAEandiCA teleconsultation network improves the efficacy of anti-VEGF therapy in retinal diseasesJ Telemed Telecare201319843744224162839
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date